Urothelial Carcinoma Clinical Trials
Urothelial Carcinoma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for urothelial Carcinoma. Corterve aggregates actively recruiting Urothelial Carcinoma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Urothelial Carcinoma studies
- Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialNCT07061964PHASE2National Cancer Institute (NCI)Birmingham, Alabama
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)NCT04198766PHASE1, PHASE2Inhibrx Biosciences, IncDuarte, California
- Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaNCT07265947PHASE2Tyra Biosciences, IncAtlanta, Georgia
- Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyNCT05987241PHASE2, PHASE3National Cancer Institute (NCI)Phoenix, Arizona
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialNCT06770582PHASE2National Cancer Institute (NCI)Fayetteville, Arkansas
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasNCT07285044PHASE2Mayo ClinicJacksonville, Florida
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerNCT06524544PHASE3National Cancer Institute (NCI)Phoenix, Arizona
- Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerNCT06809140PHASE2Matthew GalskyDuarte, California
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerNCT04628767PHASE2, PHASE3National Cancer Institute (NCI)Kingman, Arizona
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382PHASE2National Cancer Institute (NCI)Birmingham, Alabama
- Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALANCT06948552PHASE2Henry Ford Health SystemDetroit, Michigan
- Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER TrialNCT07726602OHSU Knight Cancer InstitutePortland, Oregon
Urothelial Carcinoma trials by state
Urothelial Carcinoma trials by metro
Frequently asked questions
- How do I find recruiting Urothelial Carcinoma clinical trials?
- Corterve aggregates actively recruiting Urothelial Carcinoma studies from the public ClinicalTrials.gov registry. Browse the studies listed on this page or take a free health assessment to see trials you may qualify for based on your profile.
- Are Urothelial Carcinoma clinical trials free to join?
- Study participation is typically free — research sponsors cover the cost of the investigational treatment and study-related visits. Many trials also compensate participants for time and travel. Details vary by study.
- Who can take part in a Urothelial Carcinoma clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.